$1.45 0.7%
DRRX Stock Price vs. AI Score (Last 150 days)
Data gathered: July 18

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About DURECT

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program.


DURECT
Price $1.45
Target Price Sign up
Volume 21,590
Market Cap $42M
Year Range $0.5 - $1.78
Dividend Yield 0%
Revenue per Employee $105,474
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '241.8M3.4M-1.6M-7.6M-5.7M-0.250
Q4 '232.6M3.3M-740,000-1.4M-6.4M-0.100
Q3 '231.7M4.1M-2.4M-3M-8.9M-0.140
Q2 '232.1M4.2M-2.1M-11M-9.5M-0.420
Q1 '231.9M4.5M-2.5M-12M-11M-0.470

Insider Transactions View All

Robertson Judith J. filed to buy 356,132 shares at $0.9.
August 22 '22
Robertson Judith J. filed to buy 346,720 shares at $0.8.
August 22 '22
Robertson Judith J. filed to buy 267,059 shares at $0.8.
August 19 '22
Robertson Judith J. filed to buy 275,189 shares at $0.8.
August 19 '22
Maderis Gail J filed to buy 200,000 shares at $0.7.
August 12 '22

What is the Market Cap of DURECT?

The Market Cap of DURECT is $42M.

How Many People Work at DURECT?

As of our latest update, DURECT employed approximately 78 people worldwide. However, it's important to note that DURECT's workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.

What is DURECT's revenue per employee?

$105,474. To calculate DURECT's revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.

What is the current stock price of DURECT?

Currently, the price of one share of DURECT stock is $1.45.

How can I analyze the DRRX stock price chart for investment decisions?

The DRRX stock price chart above provides a comprehensive visual representation of DURECT's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling DURECT shares. Our platform offers an up-to-date DRRX stock price chart, along with technical data analysis and alternative data insights.

Does DRRX offer dividends to its shareholders?

As of our latest update, DURECT (DRRX) does not offer dividends to its shareholders. Investors interested in DURECT should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of DURECT?

Some of the similar stocks of DURECT are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.